In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy
Autor: | Tetsuya Suhara, Ming-Rong Zhang, Shigeki Hirano, Hironobu Endo, Hitoshi Shimada, Fumitoshi Niwa, Yasuyuki Kimura, Soichiro Kitamura, Masanori Ichise, Tatsushi Toda, Shunsuke Koga, Satoshi Kuwabara, Dennis W. Dickson, Naruhiko Sahara, Makoto Higuchi, Hitoshi Shinotoh, Maiko Ono |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Movement disorders Red nucleus Progressive supranuclear palsy White matter 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Neuroimaging medicine business.industry medicine.disease eye diseases 030104 developmental biology medicine.anatomical_structure Globus pallidus Neurology chemistry Neurology (clinical) medicine.symptom Pittsburgh compound B business 030217 neurology & neurosurgery Motor cortex |
Zdroj: | Movement Disorders. 34:744-754 |
ISSN: | 1531-8257 0885-3185 |
Popis: | Background [11 C]pyridinyl-butadienyl-benzothiazole 3 is a PET imaging agent designed for capturing pathological tau aggregates in diverse neurodegenerative disorders, and would be of clinical utility for neuropathological investigations of PSP. Objectives To explore the usefulness of [11 C]pyridinyl-butadienyl-benzothiazole 3/PET in assessing characteristic distributions of tau pathologies and their association with clinical symptoms in the brains of living PSP patients. Methods We assessed 13 PSP patients and 13 age-matched healthy control subjects. Individuals negative for amyloid β PET with [11 C]Pittsburgh compound B underwent clinical scoring, MR scans, and [11 C]pyridinyl-butadienyl-benzothiazole 3/PET. Results There were significant differences in binding potential for [11 C]pyridinyl-butadienyl-benzothiazole 3 between PSP patients and healthy control subjects (P = 0.02). PSP patients exhibited greater radioligand retention than healthy control subjects in multiple brain regions, including frontoparietal white matter, parietal gray matter, globus pallidus, STN, red nucleus, and cerebellar dentate nucleus. [11 C]pyridinyl-butadienyl-benzothiazole 3 deposition in frontoparietal white matter, but not gray matter, was correlated with general severity of parkinsonian and PSP symptoms, whereas both gray matter and white matter [11 C]pyridinyl-butadienyl-benzothiazole 3 accumulations in the frontoparietal cortices were associated with nonverbal cognitive impairments. Autoradiographic and fluorescence labeling with pyridinyl-butadienyl-benzothiazole 3 was observed in gray matter and white matter of PSP motor cortex tissues. Conclusions Our findings support the in vivo detectability of tau fibrils characteristic of PSP by [11 C]pyridinyl-butadienyl-benzothiazole 3/PET, and imply distinct and synergistic contributions of gray matter and white matte tau pathologies to clinical symptoms. [11 C]pyridinyl-butadienyl-benzothiazole 3/PET potentially provides a neuroimaging-based index for the evolution of PSP tau pathologies promoting the deterioration of motor and cognitive functions. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. |
Databáze: | OpenAIRE |
Externí odkaz: |